CFO of Biohaven Pharmaceutical Holding Co (30-Year Financial, Insider Trades) James Engelhart (insider trades) sold 73,725 shares of BHVN on 06/11/2020 at an average price of $66.09 a share. The total sale was $4.9 million.
Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders. Biohaven Pharmaceutical Holding Co Ltd has a market cap of $3.86 billion; its shares were traded at around $66.00 with and P/S ratio of 3300.00. GuruFocus has detected 2 severe warning signs with Biohaven Pharmaceutical Holding Co Ltd. .
CFO Recent Trades:
- CFO James Engelhart sold 73,725 shares of BHVN stock on 06/11/2020 at the average price of $66.09. The price of the stock has decreased by 0.14% since.
Directors and Officers Recent Trades:
- Chief Commercial Officer John Tilton sold 52,000 shares of BHVN stock on 06/10/2020 at the average price of $67.38. The price of the stock has decreased by 2.05% since.
- SVP, Clinical Operations Kimberly Gentile sold 600 shares of BHVN stock on 06/08/2020 at the average price of $70.05. The price of the stock has decreased by 5.78% since.
For the complete insider trading history of BHVN, click here
.